Loading…
Employees: 950
Size Wuhan Keqian Biology (688526.SS) is a China Health Care company (Biotechnology) with a market value of $814M, the 2716th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.64 on 6 Nov 2026.
Performance Over six months the shares fell 19.2%, against -18.1% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 22.2% over the last twelve months (peer median +0.6%); the operating margin is 19.9% (peer median -61.7%).
Valuation It trades at 16.6× forward earnings against a peer median of 38.4× (cheapest of 4).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.7 points below its cost of capital (9.7% WACC).
Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥787M | CN¥946M | CN¥938M | CN¥1.06B | CN¥997M |
| Revenue growth | — | +1% | -11% | +6% | — |
| Gross profit | CN¥549M | CN¥613M | CN¥579M | CN¥738M | CN¥709M |
| EBITDA | n/a | CN¥480M | CN¥418M | CN¥469M | CN¥468M |
| Net income | CN¥227M | CN¥419M | CN¥382M | CN¥396M | CN¥410M |
| Free cash flow | CN¥272M | CN¥423M | CN¥326M | CN¥494M | CN¥377M |
| Capital expenditure | CN¥127M | CN¥124M | CN¥107M | CN¥105M | CN¥103M |
| Total debt | CN¥38.1M | CN¥6.68M | CN¥39.0M | CN¥327M | CN¥328M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688526.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | -10.1% | 9th highest of 21 |
| 6-month return | -19.2% | -18.1% | 10th highest of 19 |
| Distance from 52-week high | -34.6% | -44.9% | 4th highest of 21 |
| Revenue growth (TTM) | -22.2% | +0.6% | 5th lowest of 16 |
| Operating margin | 19.9% | -61.7% | 2nd highest of 18 |
| Forward P/E | 16.6× | 38.4× | cheapest of 4 |
| Growth the price implies (Req g, 7 yrs) | 8.8% | 20.1% | 3rd least demanding of 6 |
| Growth delivered (Del g) | +2.4% | +14.7% | 2nd lowest of 6 |
| Hurdle (Req g minus delivered) | +6.4 pp | +8.3 pp | 3rd least demanding of 6 |
| ROIC minus cost of capital | -1.7 pp | -20.3 pp | 3rd highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 16.6× | 8.8% | +2.4% |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 38.4× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | n/a | 48.8% | +14.7% |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | n/a | -12.3% | -10.9% |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 20.0× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | n/a | -9.9% | +39.2% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 135.6× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | n/a | 43.2% | +21.5% |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | n/a | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | n/a | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | n/a | n/a | n/a |